17th International Myeloma Workshop

Efficacy and Safety of Carfilzomib Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies

High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma

The results of a study presented at the 17th International Myeloma Workshop might provide the rational for predicting multiple myeloma (MM) patient status for targeted and immune therapy.
Risk of Progression Across Age and Race for Patients with Smoldering Multiple Myeloma

Risk of Progression Across Age and Race for Patients with Smoldering Multiple Myeloma

There exists a higher rate of multiple myeloma (MM) progression in younger patients with smoldering multiple myeloma patients than old ones.
Fractures and Survival in Multiple Myeloma: Results from a Population-Based Study

Fractures and Survival in Multiple Myeloma: Results from a Population-Based Study

Multiple myeloma (MM) patients with a fracture at diagnosis have a higher risk of dying compared to patients without a fracture
CAR T-cell

Single-Cell Dissection of Resistance to Anti-BCMA CAR-T Cell Therapy

Researchers have uncovered that both T cell-intrinsic and microenvironment factors are associated with clinical response to anti-BCMA CAR-T cells in refractory myeloma.

Clinical Responses and Pharmacokinetics of Fully Human BCMA Targeting CAR-T Cell Therapy in Relapsed/Refractory...

This early-stage clinical study, presented at the 17th International Myeloma Workshop, exhibited the safety and efficacy of CT103A in heavily pretreated R/R multiple myeloma (RRMM) patients.

Curated Journal Abstracts

click me